Company: XOMAP
Filing Date: 2025-10-03
Form Type: 424B5
Source: 0001193125-25-230393
Chunk: 82

Company: XOMA Royalty Corp
Filing Date: 2025-10-03
Form: 424B5
Chunk 82
---
 Company is not the surviving entity;                                                |

| • |     | the sale of all or substantially all of our assets in one transaction or a series of related transactions; |

| • |     | any completed tender offer or exchange offer involving holders of Common Stock in which more than 50% of the                            
 Common Stock not held by us or any other person making such offer is converted or exchanged into other securities, cash or property; or |

17

| • |     | any reclassification of Common Stock or any compulsory share exchange by which our Common Stock is effectively 
 converted into or exchanged for other securities, cash or property (but not a reverse stock split).            |

If the holders of Common Stock are given a choice as to the securities, cash or property to be received in a fundamental transaction, the holders of Series X Preferred Stock will be given the same choice on conversion of such holders’ shares. Voting Rights.The Series X Preferred Stock has no voting rights, except to the extent expressly provided in our Certificate of Incorporation or as otherwise required by law. However, so long as at least 50% of the authorized shares of Series X Preferred Stock are outstanding, we may not take any of the following actions without the affirmative consent of holders of a majority of the outstanding Series X Preferred Stock:

| • |     | amend our Certificate of Incorporation, By-laws or other charter                                                                         
 documents so as to materially, specifically and adversely affect the preferences, rights, or privileges of the Series X Preferred Stock; |

| • |     | issue additional shares of Series X Preferred Stock or increase or decrease the number of authorized shares of 
 Series X Preferred Stock;                                                                                      |

| • |     | sell, assign, monetize, pledge or otherwise divest or encumber our rights under any material license agreement, 
 joint venture or other partnership agreement to which we are a party and involving any drug or drug candidate;  |

| • |     | issue or commit to issue any other equity securities, with certain exceptions; |

| • |     | issue any equity-based award or compensation to certain of our officers, unless the award has been unanimously                                     
 approved by our compensation committee at a time when a designee appointed by the Series X Preferred holders is then serving on that committee; or |

| • |     | enter into any agreement or understanding to take any of the actions listed above. |

Anti-takeover Effects of Provisions of our Certificate of Incorporation and By-lawsand Delaware Law Certificate of Incorporation and By